Adetola Kassim, MD
Hematology · Nashville, TNNPI 1730295742
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.4%. Reporting peaked in 2021 at $6,786 and has fallen 92.2% since, to $531 in 2025.
Across 33 payments — averaging $793.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Global Blood Therapeutics, Inc.$4K
- Bristol Myers Squibb$3K
- One Lambda, Inc.$3K
- Terumo BCT, Inc.$3K
- Sanofi$2K
- National Marrow Donor Program$2K
- plus $8K from 12 others
Across 10 payments — averaging $3135.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$16K
- National Marrow Donor Program$13K
- Pharmacyclics LLC, An Abbvie Company$3K
What the payments were for
- Consulting fees$13,43751%
- Speaking & faculty fees$5,65022%
- Travel & lodging$5,35620%
- Food & beverage$1,4145%
- Education$3291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Global Blood Therapeutics, Inc. | 2 | $4,297 |
| Bristol Myers Squibb | 2 | $3,000 |
| One Lambda, Inc. | 2 | $2,974 |
| Terumo BCT, Inc. | 1 | $2,770 |
| Sanofi | 1 | $2,420 |
| National Marrow Donor Program | 3 | $2,371 |
| Biolinerx USA, Inc. | 1 | $2,250 |
| Omeros Corporation | 1 | $2,250 |
| GSK | 1 | $1,625 |
| Pfizer | 3 | $1,103 |
| Astellas Pharma US Inc | 3 | $269 |
| Karyopharm Therapeutics Inc. | 3 | $265 |
| Gilead | 2 | $187 |
| Genetix Biotherapeutics Inc | 4 | $136 |
| Iovance Biotherapeutics, Inc. | 1 | $81 |
| Sanofi-aventis U.S. LLC | 1 | $71 |
| Agios Pharmaceuticals, Inc. | 1 | $61 |
| Johnson & Johnson | 1 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,187 in reported general payments places this provider in the 75th percentile of 23 hematology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 35 | $872,929 |
| RevlimidLenalidomide | 33 | $596,020 |
| Lenalidomide | 34 | $433,472 |
| ImbruvicaIbrutinib | 25 | $380,943 |
| PomalystPomalidomide | 14 | $358,924 |
| VyndamaxTafamidis | 11 | $237,600 |
| JakafiRuxolitinib Phosphate | 11 | $172,759 |
| PrevymisLetermovir | 12 | $83,179 |
| EliquisApixaban | 27 | $22,026 |
| Xtampza ErOxycodone Myristate | 21 | $14,102 |
| Deferasirox | 19 | $13,371 |
| XareltoRivaroxaban | 11 | $7,384 |
| ValacyclovirValacyclovir Hcl | 119 | $5,051 |
| Imatinib Mesylate | 14 | $3,880 |
| Oxycodone Hcl | 48 | $830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCRezurock | $71 | $872,92935 claims |
| Bristol Myers SquibbRevlimid | $3,000 | $596,02033 claims |
| PfizerVyndamax, Eliquis | $1,103 | $259,62638 claims |
| Johnson & JohnsonXarelto | $57 | $7,38411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 23 hematology providers in Tennessee.
Other hematology in Nashville
- Stephen StricklandNashville$120K
- Michael SavonaNashville$100K
- Ashwin KishtagariNashville$88K
- Navneet MajhailNashville$58K
- Michael ByrneNashville$18K
- Robert CornellNashville$17K
- Anne NeffNashville$5K
- Silvia BuntingNashville$4K
- Wesam AhmedNashville$4K
- Phyu Thin NaingNashville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.